EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

CREB3L1 facilitates pancreatic tumor progression and reprograms intratumoral tumor-associated macrophages to shape an immunotherapy-resistance microenvironment

Haiyan Xu, Shengbai Xue, Yang Sun, Jingyu Ma, Shumin Li, Yanling Wang, Tiebo Mao, Weiyu Ge, Ming Yue, Daiyuan Shentu, Wenxin Lu, Yongchao Wang und 6 weitere

Journal for ImmunoTherapy of Cancer · 2025-01 · 13 (1) · e010029

DOI: 10.1136/jitc-2024-010029 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 06.01.2025. Verfasst von Haiyan Xu und 17 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Systems Medicine for Cancer of Oncology Department and Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shangha…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Tumor Microenvironment, Cyclic AMP Response Element-Binding Protein, Tumor-Associated Macrophages. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Scientific and Techno-logical Innovation Project of Science and Technology Commission of Shanghai Municipality, Innovative Research Team of High-level Local University in Shanghai, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To date, a growing body of evidence suggests that unfolded protein response (UPR) sensors play a vital role in carcinogenesis. However, it remains unclear whether they are involved in pancreatic ductal adenocarcinoma (PDAC) and how they relate to clinical outcomes. This study aims to investigate the biological function and mechanism of how a novel UPR sensor, CREB3L1 works in PDAC and further evaluate its clinical application prospect.

Methods

We tested UPR signaling including CREB3L1 in Thapsigargin-treated PDAC cells. Subsequently, we defined CREB3L1 expression and further analyzed its expression with clinical characteristics in PDAC. Then, we established gene-modified cells to determine whether CREB3L1 functions in cell proliferation and migration capacity. Besides, we constructed subcutaneously and orthotopically transplanted mice models to verify their progrowing function and pulmonary metastasis models to prove their proinvasion role. What’s more, RNAseq, qPCR, Western blotting, immunohistochemistry and multicolor flow cytometry experiments were used to explore the mechanism of how CREB3L1 worked in PDAC. Lastly, CREB3L1 expression correlation with PDAC immunotherapy outcome and immune cell signatures were explored in the patients with advanced PDAC who received PD-1 antibody therapy.

Results

We first confirmed CREB3L1 could be induced by endoplasmic reticulum stressor and found its aberrant activation was associated with poorer overall survival in PDAC patients indicating the protumor function of the new UPR sensor. Functionally, we confirmed CREB3L1 contributing to PDAC malignant progression including growth and metastasis by multiple in in vitro and in vivo models. Mechanistically, CREB3L1 upregulated COL3A1 and promoted dense stroma formation for facilitating PDAC and knocking down COL3A1 disrupted CREB3L1 protumor function. Furthermore, CREB3L1-induced TAM polarization toward an M2 phenotype and reduced the infiltration of CD8 + T cells. Clinically, CREB3L1 correlated with immune cell signatures as well as immune checkpoint blockade (ICB) treatment response and outcome that CREB3L1aberrant activation indicated poorer efficacy and worse prognosis than the low in PDAC which might empower clinical decision.

Conclusions

Collectively, this study revealed CREB3L1 facilitated PDAC progression, shaped an immune exclude tumor microenvironment and distinguished therapy response and outcome of ICB therapy indicating CREB3L1 could be a promising novel molecular target and biomarker for PDAC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsTumor MicroenvironmentCyclic AMP Response Element-Binding ProteinTumor-Associated MacrophagesImmunotherapyHumansMiceAnimalsDisease ProgressionCarcinoma, Pancreatic DuctalCell Line, TumorFemaleMaleNerve Tissue ProteinsDrug Resistance, Neoplasm

Stichwörter der Autor:innen

Combination therapyImmunotherapyIntratumoralMonocyteTumor microenvironment - TME

Substanzen

Cyclic AMP Response Element-Binding ProteinCREB3L1 protein, humanNerve Tissue Proteins

Autor:innen und Institutionen

  • State Key Laboratory of Systems Medicine for Cancer of Oncology Department and Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China liweiwang@shsmu.edu.cn uhaiyan…
  • State Key Laboratory of Systems Medicine for Cancer of Oncology Department and Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Institute of Molecular Medicine (IMM), State Key Laboratory of Oncogenes and Related Genes, Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Department of Infectious Diseases, Shanghai Sixth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China liweiwang@shsmu.edu.cn uhaiyan@sjtu.edu.cn wangyu4tc@163.com lilytsai1990@163.com.

Förderung

  • Scientific and Techno-logical Innovation Project of Science and Technology Commission of Shanghai Municipality
  • Innovative Research Team of High-level Local University in Shanghai
  • National Natural Science Foundation of China
  • Project from CSCO Clinical Oncology Research Foundation
  • Shanghai Municipal Commission of Health and Family Planning
  • Clinical Research Plan of SHDC
  • Shanghai leading talents project
  • Shanghai Municipal Education Commission-Gao Feng Clinical Medicine Grant Support

Zitieren

APA

Xu, H., Xue, S., Sun, Y., Ma, J., Li, S., Wang, Y., Mao, T., Ge, W., Yue, M., Shentu, D., Lu, W., Wang, Y., Hu, J., Cui, J., Zhang, X., Cai, L., Wang, Y., & Wang, L. (2025). CREB3L1 facilitates pancreatic tumor progression and reprograms intratumoral tumor-associated macrophages to shape an immunotherapy-resistance microenvironment. Journal for ImmunoTherapy of Cancer, 13(1), e010029. https://doi.org/10.1136/jitc-2024-010029

Vancouver

Xu H, Xue S, Sun Y, Ma J, Li S, Wang Y, et al. CREB3L1 facilitates pancreatic tumor progression and reprograms intratumoral tumor-associated macrophages to shape an immunotherapy-resistance microenvironment. Journal for ImmunoTherapy of Cancer. 2025;13(1):e010029. doi:10.1136/jitc-2024-010029

BibTeX
@article{Xu2025,
  author = {Xu, Haiyan and Xue, Shengbai and Sun, Yang and Ma, Jingyu and Li, Shumin and Wang, Yanling and Mao, Tiebo and Ge, Weiyu and Yue, Ming and Shentu, Daiyuan and Lu, Wenxin and Wang, Yongchao and Hu, Jiong and Cui, Jiujie and Zhang, Xiaofei and Cai, Li and Wang, Yu and Wang, Liwei},
  title = {CREB3L1 facilitates pancreatic tumor progression and reprograms intratumoral tumor-associated macrophages to shape an immunotherapy-resistance microenvironment},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {1},
  pages = {e010029},
  doi = {10.1136/jitc-2024-010029}
}
Kostenlos starten →